HomePfizer Vaccine efficacy against Omicron drops to 40% in kids 12-18 from...

Pfizer Vaccine efficacy against Omicron drops to 40% in kids 12-18 from 67% in 5-11

Published on

The Pfizer–BioNTech vaccine was found to be 68% effective in reducing hospitalization from Omicron variant in children aged 5-11, but in adolescents aged 12-18, it was only 40% effective.

Although the Pfizer–BioNTech COVID-19 vaccine became available in October for children age 5-11, many parents have been hesitant to have them vaccinated.

As of March 16, only 27 percent had received two vaccine doses, according to CDC data.

A national study published March 30 by The New England Journal of Medicine now reports that vaccination of 5- to 11-year-olds reduced hospitalizations with COVID-19 by more than two thirds during the omicron surge and protected against severe illness.

The study, co-led by Adrienne Randolph, MD, MSc, at Boston Children’s Hospital and the Centers for Disease Control and Prevention, also confirms that vaccination reduced COVID-19 hospitalization in adolescents age 12-18 and protected strongly against severe illness, in line with a study earlier this year.

Efficacy of Pfizer Covid-19 Vaccine against Omicron drops to 40% in kids 12-18 from 67% in 5-11
Efficacy of Pfizer Covid-19 Vaccine against Omicron drops to 40% in kids 12-18 from 67% in 5-11

“The reason for a child to get a COVID-19 vaccine is to prevent severe complications of SARS-CoV-2 infection, including hospitalization,” says Randolph. “This evidence shows that vaccination reduces this risk substantially in 5- to 11-year-olds. And while vaccination provided adolescents with lower protection against hospitalization with omicron versus delta, it prevented critical illness from both variants.”

The study tapped data from the national Overcoming COVID-19 Network, which Randolph launched in 2020. It included 1,185 children with COVID-19 at 31 pediatric hospitals across the U.S.: 918 adolescents aged 12 to 18 and 267 children aged 5 to 11. The team also enrolled patients of similar age who were hospitalized for other reasons and served as controls.

The study spanned July 2021 through February 17, 2022, during the delta and omicron surges. In children 5 to 11, vaccine benefits could only be assessed during omicron, as the vaccine was not approved for them until October 2021.

Pfizer Vaccine efficacy against Omicron drops to 40% in kids 12-18 from 67% in 5-11
Pfizer Vaccine efficacy against Omicron drops to 40% in kids 12-18 from 67% in 5-11

Study findings and conclusions

  • Overall, 88 percent of patients hospitalized with COVID-19 were unvaccinated, and 25 percent had critical illness requiring life-supporting interventions.
  • Of children ages 5-11 hospitalized with COVID-19, 92 percent were unvaccinated. Sixteen percent were critically ill, needing life support measures such as intubation. Of these, 90 percent were unvaccinated.
  • Of adolescents ages 12-18 hospitalized with COVID-19, 87 percent were unvaccinated. Twenty-seven percent had critical illness, and of these, 93 percent were unvaccinated. Two children died.

Based on their observations, the researchers calculate that:

  • Among children age 5-11, two doses of the Pfizer–BioNTech vaccine were 68 percent effective in preventing hospitalization during omicron. Because this age group only recently became eligible for vaccine, numbers were not sufficient to evaluate critical illness separately.
  • Among adolescents age 12-18, vaccination was 92 percent effective against hospitalization with the delta variant, falling to 40 percent with the omicron variant. In terms of preventing critical illness, vaccination was 96 percent effective in preventing critical illness during the delta period and 79 percent during the omicron wave.

Vaccination rates remain low in children and teens

The Pfizer/BioNTech vaccine became available for children age 16-18 in December 2020, for children age 12-15 in May 2021, and for children age 5-11 in October 2021. Yet, as of March 16, 2002, just 57 percent of 12- to 17-year-olds and only 27 percent of 5- to 11-year-olds had received two vaccine doses, according to CDC data gathered by the American Academy of Pediatrics.

“We hope our findings will help parents make the decision to vaccinate their children and teens against COVID-19,” says Randolph. “The benefits clearly outweigh the risks, as severe infections in childhood can have long-term consequences.”

Source: 10.1056/NEJMoa2117995

Image Credit: Getty

You were reading: Pfizer Vaccine efficacy against Omicron drops to 40% in kids 12-18 from 67% in 5-11

Latest articles

Neuroscience Breakthrough: Study Pinpoints Brain Activity That Helps Prevent Us From Getting Lost

No more wrong turns: Explore the findings of a groundbreaking study revealing the brain's...

Brief Anger Hampers Blood Vessel Function Leading to Increased Risk of Heart Disease and Stroke – New Study

New research in the Journal of the American Heart Association unveils how fleeting bouts...

New Blood Test Pinpoints Future Stroke Risk – Study Identifies Inflammatory Molecules as Key Biomarker

Breakthrough Discovery: A Simple Blood Test Can Gauge Susceptibility to Stroke and Cognitive Decline...

Enceladus: A Potential Haven for Extraterrestrial Life in its Hidden Ocean Depths

Enceladus: Insights into Moon's Geophysical Activity Shed Light on Potential Habitability In the vast expanse...

More like this

Neuroscience Breakthrough: Study Pinpoints Brain Activity That Helps Prevent Us From Getting Lost

No more wrong turns: Explore the findings of a groundbreaking study revealing the brain's...

Brief Anger Hampers Blood Vessel Function Leading to Increased Risk of Heart Disease and Stroke – New Study

New research in the Journal of the American Heart Association unveils how fleeting bouts...

New Blood Test Pinpoints Future Stroke Risk – Study Identifies Inflammatory Molecules as Key Biomarker

Breakthrough Discovery: A Simple Blood Test Can Gauge Susceptibility to Stroke and Cognitive Decline...